Measuring the Impact of Onco4D® Guidance on Chemotherapy Selection and Outcomes

Condition(s) studied

Investigational drug(s) / intervention(s)

Onco4D Biodynamic Chemotherapy Selection Assay: Functional precision medicine test to predict response to candidate chemotherapeutic agents

Study summary

Millions of cancer patients each year receive chemotherapy causing adverse side effects that lower quality of life without prolonging it. Reliable identification of ineffective therapies can eliminate needless human suffering while increasing overall probability of positive response to treatment. Chemotherapy resistance profiling entails testing whether a patient exhibits strong resistance to a therapy prior to its final selection by the oncologist.

The Onco4D® chemotherapy selection assay has recently emerged as means to measure the response of intact tumor biopsies to applied therapeutics by using Doppler detection of infrared light scattered from intracellular motions inside living tissue (known as Motility Contrast Tomography or MCT). Several studies have shown this phenotypic profiling technique to offer high accuracy predicting response and resistance to chemotherapy\[1-5\].

Eligibility

Primary outcome measure(s)

• Pathologic complete response (pCR) to neoadjuvant chemotherapy — 1 year
  Difference in pathologic complete response (pCR) to neoadjuvant chemotherapy among recipients of Onco4D® guided therapy as compared to baseline unguided pCR rates

Trial sites (1)

Other trials for the same condition